CN103108628B - 用于输注b型羊毛硫抗生素的制剂 - Google Patents

用于输注b型羊毛硫抗生素的制剂 Download PDF

Info

Publication number
CN103108628B
CN103108628B CN201180038723.5A CN201180038723A CN103108628B CN 103108628 B CN103108628 B CN 103108628B CN 201180038723 A CN201180038723 A CN 201180038723A CN 103108628 B CN103108628 B CN 103108628B
Authority
CN
China
Prior art keywords
formulation
compound
lantibiotic
type
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180038723.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103108628A (zh
Inventor
A·N·阿普尔亚德
S·N·沃德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novacta Biosystems Ltd
Original Assignee
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Ltd filed Critical Novacta Biosystems Ltd
Publication of CN103108628A publication Critical patent/CN103108628A/zh
Application granted granted Critical
Publication of CN103108628B publication Critical patent/CN103108628B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180038723.5A 2010-08-11 2011-08-09 用于输注b型羊毛硫抗生素的制剂 Expired - Fee Related CN103108628B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1013513.5A GB201013513D0 (en) 2010-08-11 2010-08-11 Formulations
GB1013513.5 2010-08-11
PCT/GB2011/001191 WO2012020219A2 (en) 2010-08-11 2011-08-09 Formulations for infusion of type b lantibiotics

Publications (2)

Publication Number Publication Date
CN103108628A CN103108628A (zh) 2013-05-15
CN103108628B true CN103108628B (zh) 2015-08-05

Family

ID=42931511

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180038723.5A Expired - Fee Related CN103108628B (zh) 2010-08-11 2011-08-09 用于输注b型羊毛硫抗生素的制剂

Country Status (9)

Country Link
US (1) US9192569B2 (enExample)
EP (1) EP2603204A2 (enExample)
JP (1) JP5865374B2 (enExample)
CN (1) CN103108628B (enExample)
CA (1) CA2807206A1 (enExample)
EA (1) EA024344B1 (enExample)
GB (1) GB201013513D0 (enExample)
MX (1) MX2013001470A (enExample)
WO (1) WO2012020219A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CN109620979B (zh) * 2018-12-29 2020-09-01 福建师范大学 低离子休克提高氨基糖苷类抗生素杀灭持留菌效率的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1700894A (zh) * 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
WO2007083112A2 (en) * 2006-01-17 2007-07-26 Novacta Biosystems Limited Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae
US20100179207A1 (en) * 2009-01-14 2010-07-15 Novacta Biosystems Limited Compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1013513A (en) 1963-03-25 1965-12-15 Watney Combe Reid & Co Ltd Improvements in and relating to hopping beer
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (enExample) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
ATE255165T1 (de) 1994-09-12 2003-12-15 Aventis Pharma Gmbh Rekombinantes mersacidin und verfahren zu seiner herstellung
DE69629691T2 (de) 1995-06-23 2004-02-26 Ambi, Inc. Verfahren zur kontrolle von antibiotikaresistenten grampositiven bakterien und behandlung von infektionen
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
KR20030017569A (ko) 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US7199230B2 (en) 2002-10-10 2007-04-03 Molichem Medicines, Inc. Nucleic acids encoding duramycin
ATE356143T1 (de) 2003-07-18 2007-03-15 Vicuron Pharm Inc Antibiotikum 107891, dessen faktoren a1 und a2, pharmazeutisch unbedenkliche salze und zusammensetzungen, und anwendung davon
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
JP2007523092A (ja) 2004-02-17 2007-08-16 キャンサーバックス コーポレイション 新脈管形成阻害のための方法および組成物
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
CA2623624A1 (en) 2005-09-27 2007-04-05 Novacta Biosystems Limited Variants of the lantibiotic mersacidin and their use
ES2744816T3 (es) 2006-10-27 2020-02-26 Capsugel Belgium Nv Cápsulas duras de hidroxipropil metil celulosa y proceso de fabricación
US20110150917A1 (en) 2007-06-12 2011-06-23 The University Of British Columbia Small Cationic Antimicrobial Peptides
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
KR20110086582A (ko) 2008-11-24 2011-07-28 센티넬라 파마세티컬즈, 인크. 항균활성이 강화된 란티바이오틱 카르복시아미드 유도체
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
KR20110122139A (ko) 2009-02-04 2011-11-09 노박타 바이오시스템스 리미티드 액타가르딘 유도체
CA2789164A1 (en) 2010-02-02 2011-08-11 Novacta Biosystems Limited Lantibiotic salts
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
JP2013531026A (ja) 2010-07-14 2013-08-01 ノヴァクタ バイオシステムズ リミティッド Ｂ型ランチビオティックを含む製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1700894A (zh) * 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
WO2007083112A2 (en) * 2006-01-17 2007-07-26 Novacta Biosystems Limited Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae
US20100179207A1 (en) * 2009-01-14 2010-07-15 Novacta Biosystems Limited Compounds

Also Published As

Publication number Publication date
WO2012020219A3 (en) 2012-04-05
EP2603204A2 (en) 2013-06-19
WO2012020219A2 (en) 2012-02-16
CA2807206A1 (en) 2012-02-16
MX2013001470A (es) 2013-05-14
JP2013533304A (ja) 2013-08-22
EA024344B1 (ru) 2016-09-30
EA201291463A1 (ru) 2013-07-30
CN103108628A (zh) 2013-05-15
US20130137630A1 (en) 2013-05-30
JP5865374B2 (ja) 2016-02-17
US9192569B2 (en) 2015-11-24
GB201013513D0 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
US20220354786A1 (en) Suspension comprising a protein particle suspended in a non-aqueous vehicle
CN104000783B (zh) 头孢喹肟脂质体
JP2021120415A (ja) アントラサイクリン製剤
RS60119B1 (sr) Poboljšane formulacije levosimendana za intravensko davanje kao infuzija ili injekcija i infuzioni koncentrat
CN103108628B (zh) 用于输注b型羊毛硫抗生素的制剂
DE102004022927A1 (de) 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
RU2315623C2 (ru) Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата
JPH03193735A (ja) グリコペプチド系抗生物質の安定化組成物
KR20210054068A (ko) 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제
IL270686B (en) Derivatives of glycopeptides and their uses
KR20220034053A (ko) 재조합 단백질의 안정적인 제형
KR101801177B1 (ko) 안정한 노카티아신 동결건조 주사 제제
CN115475230B (zh) 一种卡非佐米纳米乳混悬冻干制剂及其制备方法
WO2018184540A1 (zh) 包含组氨酸缓冲体系的英夫利西单抗组合物
US20210101929A1 (en) Method for stabilizing protein comprising formulations by using a meglumine salt
CN112601541B (zh) 口服给药的生物聚合物制剂
EP4559483A1 (en) Hyaluronic acid derivative drug composition and drug composition
EP4516292A1 (en) Instant nanoparticle composition and preparation method therefor
CN109078001A (zh) 一种新型万古霉素纳米脂质体组合物及其制备方法
WO2023171588A1 (ja) 抗菌薬を含有するｐｌｇａ製剤
WO2024139226A1 (zh) 含白蛋白结合型优替德隆纳米粒的药物组合物及其制备方法
WO2025017561A1 (en) A peptide composition and uses thereof
TR2021015840A2 (tr) Peptid 6.2 peptidi ile hedeflendirilmiş, antimikrobiyal ajan/ajanlar içeren nanoformülasyonlar.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150805

Termination date: 20160809

CF01 Termination of patent right due to non-payment of annual fee